Jay G. Wohlgemuth, M.D.
Chief Medical Officer, Senior Vice President, Quest Diagnostics
Jay G. Wohlgemuth, M.D., is Chief Medical Officer and Senior Vice President, Research & Development and Medical for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth is responsible for Research & Development (R&D), Medical Affairs and Medical/Lab Quality. In addition, he is responsible for improving outcomes for employees who use Quest's health benefits.
Dr. Wohlgemuth has many years of experience in medical diagnostics and research and development. He rejoined Quest in 2016 from HealthTap, a health information start-up, where he served as Senior Vice President and Chief Healthcare Officer. Prior to that, he was Senior Vice President, R&D, Medical and Chief Scientific Officer with Quest. Dr. Wohlgemuth originally joined Quest in 2009 from Genentech, where he was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. In addition, Dr. Wohlgemuth served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. He serves on the Board of Directors for the Diagnostic Labs of Oklahoma and The Anne and Henry Zarrow Charitable Foundation.
Dr. Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.
William S. Dalton, Ph.D., M.D.
Board Vice Chair
Founder, Executive Chairman, M2Gen
Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. William “Bill” S. Dalton is the Founder and Executive Chairman of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.
Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer CareTM approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. He is also recognized as a founder of ORIEN, an alliance of cancer centers who have agreed to use the Total Cancer Care protocol to generate and share data for collaborative research and learning. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
Mark P. Stevenson, M.B.A.
Executive Vice President and Chief Operating Officer, Thermo Fisher Scientific
Mark Stevenson has been Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific since August 2017, with responsibility for Thermo Fisher’s life sciences, analytical instruments and laboratory products businesses as well as the company’s innovation and digital strategy. He joined the company as Executive Vice President and President, Life Sciences Solutions, through the acquisition of Life Technologies in 2014.
Mark previously served as President and Chief Operating Officer of Life Technologies, and President and Chief Operating Officer of Applied Biosystems prior to its merger with Invitrogen Corporation in 2008.
Mark received his M.B.A. from Henley Management School in the U.K. and his bachelor’s degree in chemistry from the University of Reading, also in the U.K.
Michael J. Pellini, M.D., M.B.A.
Managing Partner, Section 32
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017.
He currently serves as a member of the Board of
Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies
and the Mission Hospital Foundation. As a physician with more than twenty years of
executive experience with companies at the forefront of clinical diagnostics
and genomics, Dr. Pellini brings a breadth of understanding in personalized
medicine, with a particular interest and focus on defeating cancer. Dr. Pellini
is a member of the President’s Leadership Council at Thomas Jefferson
University and Jefferson Health, as well as the Advisory Board for Mission
Hospital’s Cancer Institute (Provident/St. Joseph Health).
Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Jefferson Medical College.
Bonnie J. Addario
Co-Founder, Chair, GO2 Foundation for Lung Cancer
Bonnie has been an activist, advocate, educator and change agent empowering patients and giving them a strong voice in the fight against lung cancer since receiving a stage 3B diagnosis more than a decade ago. Although thrust into a role that she had never envisioned for herself, she embraced it and now considers it to be her second career and a personal calling. Recognizing the critical need for education, empowerment, advocacy and research to help patients and families, especially those without resources and support, Bonnie and her family founded the Bonnie J. Addario Lung Cancer Foundation (ALCF) in 2006, and then went on to found the Addario Lung Cancer Medical Institute (ALCMI) with her husband, Tony Addario, in 2008. Bonnie’s business acumen and skills honed in her first career as President of Olympian Oil Company and Commercial Fueling Network (CFN), as Past President of the CA Independent Oil Marketers Association (CIOMA) and as a community activist serving on diverse boards have all contributed to her work at ALCF in developing business strategies and being the Foundation’s patient voice at national/international conferences, on panels and boards, and to industry leaders, clinicians and policy makers. Bonnie’s personal interests include collecting wine, travel, sports (Go SF Giants!) and spending time with family and friends at Lake Tahoe.
Antonio L. Andreu, M.D., Ph.D.
Scientific Director, EATRIS
Toni is an M.D., Ph.D. specialized in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research.
After working at Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d’Hebron Research Institute where he became Director of the Neurosciences Research Program.
He has also been extremely active in the field of policy-making, and has held positions as the Director of the Spanish National Institute of Health Carlos III as well as the Director General for Research and Innovation at the Catalan Ministry of Health.
Vice President, Policy and Research, PhRMA
Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Mr. Burkholder directs PhRMA work on issues related to use of evidence in healthcare decision-making, health technology assessment, comparative and costeffectiveness research, Medicare coverage policy, innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies, including the Medicare Evidence Development and Coverage Advisory Committee, the Federal Coordinating Council for Comparative Effectiveness Research, Institute of Medicine Committees and President’s Council of Advisors on Science and Technology. He also is a founding member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care.
Mr. Burkholder has over 17 years of experience in healthcare policy, advocacy and
communications in the medical technology and pharmaceutical industries. Prior to
joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at
AdvaMed, the leading association of the medical device and diagnostics industries.
Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer, MacroGenics
Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development & Chief Medical Officer, joined MacroGenics in July 2020. Prior to MacroGenics, Dr. Eck served as chief medical officer of Immatics US, a company focused on TCR-based immunotherapies, and as president and chief executive officer of Aravive Biologics. Prior to these roles, Dr. Eck was Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, managing a portfolio of assets which included enzalutamide (Xtandi®), erlotinib (Tarceva®) and gilteritinib (Xospata®). Dr. Eck has also held leadership positions in drug development as Vice President of Translational Medicine and Pharmacogenomics at Eli Lilly and as Head of Clinical Oncology at Pfizer. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program. Dr. Eck currently serves as a director for Luminex Corporation (NASDAQ: LMNX) and Circulogene, and on the boards of directors for the Personalized Medicine Coalition and the Central Pennsylvania Clinic. He is also a fellow of the American Association for the Advancement of Science. Dr. Eck holds a B.A. from Kalamazoo College, an M.S. and a Ph.D. from Harvard University, and an M.D. from the University of Mississippi School of Medicine with Residency and Fellowship training at the University of Michigan.
Lori Frank, Ph.D.
Memory Screening Advisory Board, Alzheimer’s Foundation of America
Lori Frank, Ph.D. is a Senior Scientist at the RAND Corporation. Her current work is focused on methods for incorporating the consumer perspective into health outcomes research and clinical care. Prior to joining RAND, she completed her Health and Aging Policy Fellowship through the American Political Science Association Congressional Fellowship Program, with a placement at the National Institute on Aging.
She founded and served as Director of the Evaluation and Analysis Program at the Patient-Centered Outcomes Research Institute (PCORI), establishing a research program to examine stakeholder engagement, along with survey research and portfolio analysis functions. Prior to joining PCORI she served as Executive Director and Senior Research Leader, Center for Health Outcomes Research, with MEDTAP International/United BioSource Corporation, where she led the health outcomes research department with 75+ scientific staff worldwide and managed the scientific and financial performance of the Center, substantially expanding the department internationally and coordinating with other business divisions including Health Economics, Pricing and Reimbursement, Database Analytics and Epidemiology. While there she initiated and served as Principal Investigator of the Cognition Initiative, later affiliated with the Critical Path Institute PRO Consortium, a multi-sponsor patient-reported outcome measure development consortium.
She is President-Elect of the International Society for Quality of Life Research and a member of the Medical, Scientific, and Memory Screening Advisory Board of the Alzheimer's Foundation of America. Her career has focused on patient-reported outcomes measure development and assessment, and the psychological, ethical and legal aspects of memory screening and medical treatment decision-making by older adults. She has held research and teaching positions with Georgetown University Department of Psychiatry, the National Institute on Aging, Medimmune LLC/AstraZeneca and the Veteran’s Administration (VA). She completed postdoctoral training in mental health services research with the VA Health Services Research and Development program and the Department of Psychiatry, University of Arkansas School for Medical Sciences. Dr. Frank received her doctorate in human development/gerontology from the Pennsylvania State University and her master’s degree in biopsychology from the Johns Hopkins University.
President, CEO, NanoString Technologies
R. Bradley Gray has served as a member of NanoString's board of directors and as President & Chief Executive Officer since June 2010. Prior to joining the company, Mr. Gray held various positions at Genzyme, a biotechnology company acquired by Sanofi in 2011. He served as Vice President of Product & Business Development for Genzyme Genetics, the diagnostic services division of Genzyme, from June 2008 to May 2010, leading the development of molecular diagnostics and partnering activities. From September 2006 to June 2008, he served as Vice President of Business & Strategic Development for Genzyme Genetics, leading growth efforts through partnerships and licensing. Mr. Gray joined Genzyme in October 2004 as Director of Corporate Development, supporting business development and leading Genzyme Ventures, the corporate venture capital fund of Genzyme. Prior to joining Genzyme, Mr. Gray was a management consultant in the health care practice of McKinsey & Company, a global management consulting firm, from September 2000 to October 2004, where he worked with senior health care executives in the United States and Europe on a broad range of issues including pharmaceutical and diagnostic product strategy, post-merger integration, organization design and operational turnarounds. Mr. Gray received a B.A. in Economics and Management from Oxford University, where he studied as a British Marshall Scholar, and an S.B. in Chemical Engineering from the Massachusetts Institute of Technology.
Kris Joshi, Ph.D.
Executive Vice President, President, Network Solutions, Change Healthcare
Mr. Joshi is Executive Vice President and President, Network Solutions for Change Healthcare. He initially joined Change Healthcare as Executive Vice President, Products in December 2013. Prior to that, Mr. Joshi was Global Vice President for health care product strategy for the Health Sciences Global Business Unit of the Oracle Corporation. He helped launch the health sciences business unit and successfully led two acquisitions for Oracle in the life sciences space. Before joining Oracle, Mr. Joshi served in senior strategy roles in IBM’s Global Sales and Distribution organization. Prior to that, Mr. Joshi was with McKinsey and Company, where he served Fortune 500 clients on strategy issues.
Mr. Joshi holds a Bachelor's degree in mathematics from Caltech, and a Ph.D. in physics from MIT.
Peter Maag, Ph.D.
CEO, President, CareDx
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis' headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various health care and high tech companies in their growth efforts, he holds board and advisory positions at Phoenix, MolecularMD and the Personalized Medicine Coalition. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his Ph.D. from the University of Berlin, Germany.
Senior Vice President & Global Head, Experimental Medicine, GlaxoSmithKline
Anne-Marie Martin is the SVP and Global Head of the Experimental Medicine Unit in Oncology R&D at GlaxoSmithKline. In this role, Annie leads the translational medicine effort to support asset development across the four Oncology R&D platforms in Immuno-Oncology (IO), Oncology Cell Therapy (OCT), Cancer Epigenetics (CE) and Synthetic Lethality (SL). This includes clinical biomarkers, companion diagnostics, supporting novel biomarker-driven clinical designs, the Oncology Clinical and Translational Consortium, and centralizing human subject sample handling and vendor buying power. In close collaboration with TA Clinical and the EDTs and MDTs, Annie plays a vital role in utilizing a personalized medicine approach to expedite the development of innovative therapeutics for treating various oncologic and hematologic indications.
Prior to joining GSK, Annie was the SVP, Global Head of Precision Medicine at Novartis Pharmaceuticals, where she was responsible for the development, implementation and execution of the Precision Medicine Strategy supporting all clinical development, registration and commercialization. While at Novartis, Annie shared in the successful delivery of 10 NDA/sNDAs across the pipeline and she led the development and successful approval of companion diagnostics in support of 6 clinical assets including midostaurin for Flt3 mutated AML, the first BRAF NGS assay for tafinlar and mekinist in NSCLC, ceritinib for ALK mutated NSCLC, capmatinib for MET mutated NSCLC, alpelisib for PIK3CA mutated breast cancer and BCR-ABL monitoring of major molecular response for Tasigna in CML.
Annie has over 19 years of experience in the health care sector. After graduating with a PhD in Immunology and Molecular Biology from Hahnemann University (now Drexel University) she continued with her postdoctoral training at the University of Pennsylvania. During her time at the University of Pennsylvania, Annie received funding from the Susan G. Komen Foundation, the Leiomyosarcoma Foundation, Fibro-ossificans Progressiva Foundation and the NIH through a SPORE grant. In 2001, Annie assumed the role of Director of Molecular Diagnostics and Immunohistochemistry at Pennsylvania Hospital/UPHS whilst maintaining an adjunct faculty position in the Departments of Haematology and Oncology and Orthopaedic Surgery at UPENN.
In 2005 Annie joined GlaxoSmithKline. While at GSK, she assumed increasing responsibility culminating in the role of Global Head, Precision Medicine and Diagnostics and the Head of Molecular Medicine. In this capacity she led a global team responsible for the precision medicine strategy in Oncology to deliver all translational research into pipeline opportunities. In addition, she led the development of the companion diagnostic assay that supported the approvals of Tafinlar® and Mekinist™. During her tenure at GSK, Annie contributed to three NDAs and five sNDAs. From 2014-2015 Annie led the transition and integration of her team’s work to Novartis. At the completion of the integration she assumed the role of VP, Head of Biomarker Research and Diagnostic Development, Adaptimmune LLC.
In addition to serving on the board of the Personalized Medicine Coalition, Annie is a member of the Executive Committee governing the Blood Profiling Atlas in Cancer (BLOODPAC) Consortium. Annie has over 50 publications in peer-reviewed journals.
Howard McLeod, Pharm.D.
Dr. Howard McLeod is the former Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He was also the Fred Eshelman Distinguished Professor and Founding Director of the UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr. McLeod held appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center.
Dr. McLeod is also chair of the NHGRI eMERGE network external scientific panel and a recent member of the FDA committee on Clinical Pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr McLeod has been vice chair for Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE, overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of China and a professor at Central South University in Changsha, China. He directs the Pharmacogenetics for Every Nation Initiative, which aims to help developing countries use genetic information to improve National Drug Formulary decisions.
Dr. McLeod has also been an active entrepreneur, serving on the Board of Directors, Scientific Advisory Board, and as a domain expert consultant to for-profit companies. He has founded both for-profit and non-profit companies in the USA and China. Howard has published more than 475 peer reviewed papers on pharmacogenomics, applied therapeutics or clinical pharmacology and continues to work to integrate genetics principles into clinical practice to advance individualized medicine.
J. Brian Munroe
Vice President, Government Affairs, Bausch Health Companies Inc.
Brian Munroe is the founder and Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of PMC's Public Policy Committee and on the Executive Committee of PMC's Board of Directors.
A twenty-five year veteran of health care public policy, advocacy, and communications, Brian's areas of expertise include FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine. As Chairman of the Public Policy Committee, he oversees PMC's public policy initiatives and its interactions with the federal government.
Brian has created successful, stand alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently Vice President, Government Affairs at Bausch Health Companies.
Lincoln D. Nadauld, M.D., Ph.D.
Vice President, Chief of Precision Health and Academics, Intermountain Healthcare
Lincoln Nadauld founded the Intermountain Precision Genomics program with a vision of finding solutions to improve health and disease through genomics and precision medicine without increasing costs. With his vision in mind, he oversees the clinical implementation of precision genomics across Intermountain’s 24 hospitals and 160 physician clinics.
In addition, he facilitates genomic research to better understand the human genome. Nadauld conceived of and is leading the recently announced Heredigene, Population Study — a collaborative effort with deCODE Genetics in Iceland to collect and perform whole-genome sequencing on 500,000 participants in the Intermountain system.
Nadauld’s work in founding Intermountain Precision Genomics was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry, which is the highest civilian award to be bestowed by the state of Utah and honors significant contributions to science and technology. Dr. Nadauld also received the 2020 C2 Catalyst for Precision Medicine award, honoring those who improve personalized treatment for cancer patients.
He is married with five children and enjoys attending their many activities and events, as well as water sports, fishing and other athletic pursuits.
Elizabeth O'Day, Ph.D.
Chief Executive Officer and Founder, Olaris, Inc.
Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events and reducing unnecessary healthcare costs. Dr. O'Day is also the co-chair of the World Economic Forum’s Global Future Council on Biotechnology, she serves on the advisory board for the Precision Medicine Initiative and was an invited speaker at the annual meeting in Davos. She was also a "nominated change maker" and invited to attend the first United State of Women Summit convened by the White House in 2016. She participated in Vice President Joe Biden's Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.”
Dr. O’Day is also the Founder of Lizzard Fashion, an apparel company that uses fashion to promote science, and Proyecto Chispa (Project Spark), a 501c3 non-profit that recycles electronics and uses the resale of parts to build computer centers in orphanages throughout the world. Additionally, Dr. O’Day is an adjunct faculty at Boston College, teaching metabolism and entrepreneurship. She is also on the Steering Committee and a contributor for Scientific American's annual "Top 10 Emerging Technologies".
Dr. O’Day received her Ph.D. from Harvard University, where she was a National Science Foundation fellow. She was one of 11 America scientists awarded a Winston Churchill fellowship and received a Master’s of Philosophy in Chemistry from the University of Cambridge. She has a Bachelor of Science degree from Boston College in Biochemistry, where she was awarded the Rev. Finnegan Award, the most prestigious award bestowed to an undergraduate, and nearly all of the nation’s top undergraduate research honors (Beckman scholar, Goldwater Scholar, Churchill Fellow, NSF Fellow, National Institute of Chemistry Excellence Award).
Co-Founder, Genomic Health
Committed to changing the paradigm of cancer care, Kim Popovits led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the over-treatment and optimal treatment of early-stage cancer, one of the greatest issues in health care today.
Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the American Clinical Laboratory Association (ACLA), and MyoKardia. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Adviser to the Healthcare Businesswomen’s Association (HBA).
Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives.
Kim holds a Bachelor of Arts degree in Business from Michigan State University.
Hakan Sakul, Ph.D.
Vice President, Head of Diagnostics, Worldwide R & D, Pfizer Inc.
Hakan leads Pfizer’s Companion Diagnostics efforts across the Worldwide R&D organization and is also responsible for Pfizer’s internal Biobank group. His formal education includes BS (1983) and MS (1984) degrees from Ankara University in Turkey, PhD (1990) in Quantitative Genetics from the University of Minnesota as a Rotary Foundation Scholar, and postdoctoral studies in genetics at the University of California-Davis (1990-94).
Hakan worked in the biotech industry in human genetics and statistical genetics fields across multiple disease areas before moving to Parke-Davis Pharmaceuticals in 1998 to direct human genetics, statistical genetics and pharmacogenetics programs. Following the merger of Warner-Lambert/Parke-Davis with Pfizer, he has held positions of increasing responsibility in Clinical Pharmacogenomics, Molecular Profiling, and Translational Oncology. Hakan interacted closely with Pfizer’s Executive Leadership Team and the Board of Directors to define and implement Pfizer’s current companion diagnostics strategy. One of his most significant professional accomplishments was to lead the companion diagnostics program for Xalkori® (Crizotinib), Pfizer’s flagship program in companion diagnostics. Hakan served on the clinical development and drug/diagnostics submission teams and led the companion diagnostics program to a successful delivery, resulting in simultaneous FDA approvals of both the drug and the companion diagnostic test in 2011.
Hakan was then promoted to his current role to provide companion diagnostics leadership across Pfizer’s pharmaceutical pipeline. He led the internal efforts that resulted in companion diagnostics partnerships with Dako/Agilent and Siemens Healthcare Diagnostics, among others. Hakan’s contributions to precision medicine and companion diagnostics have been widely recognized through both internal and external awards, frequent speaking engagements, and press coverage. He is the author of over 30 referred scientific articles as well as many other papers, abstracts and book chapters.
Hakan is keenly interested in technologies for identification of patient sub-groups for targeted treatments and development of companion diagnostics to advance Precision Medicine for the improvement of individualized health care. He is an active member of civic clubs, and enjoys cycling, soccer, and stand-up paddle-boarding.
Michael Sherman, M.D., M.B.A., M.S.
Senior Vice President, Chief Medical Officer, Harvard Pilgrim Health Care
Dr. Michael Sherman serves as Chief Medical Officer and Senior Vice President for Harvard Pilgrim Health Care. He works with physicians and health care organizations to achieve sustainable improvements in cost and quality. He has focused the organization on introducing innovative, outcomes-based reimbursement models and developing outcomes-based payment agreements. Dr. Sherman is the chair of the Board of Managers of the Harvard Pilgrim Health Care Institute, and also serves on the Advisory Board of the Institute for Clinical and Economic Review (ICER), the Board of Directors and as co-President of the Harvard Business School Healthcare Alumni Association, the Board of Advisors for the Harvard Business School Healthcare Initiative, and Board of Overseers for Boston’s Museum of Science.
Prior to joining Harvard Pilgrim, Dr. Sherman served as Corporate Medical Director, Physician Strategies, for Humana and held several leadership positions with UnitedHealth Group, Thomson Medstat (now IBM Truven), HealthAllies and Immusol.
Dr. Sherman holds a B.A. in anthropology and natural sciences and an M.S. in biomedical anthropology from the University of Pennsylvania. He received his M.D. from Yale and an M.B.A. from the Harvard Business School.
Senior Vice President of External Affairs, Tempus
Lauren Silvis serves as Senior Vice President of External Affairs, overseeing regulatory, public policy and government affairs. Silvis most recently served as the Chief of Staff of the U.S. Food and Drug Administration. Prior to that role, she was the Deputy Center Director for Policy in FDA’s Center for Devices and Radiological Health. At the FDA, she advanced policies on clinical testing, precision medicine, and digital health. Silvis was also a partner at Sidley Austin LLP, focusing on FDA regulation of pharmaceuticals and medical devices. She graduated from Duke University and earned her law degree from Georgetown University Law Center.
Michael J. Vasconcelles, M.D.
Chief Medical Officer, Flatiron Health
Michael Vasconcelles, M.D., is Chief Medical Officer of Flatiron Health (Flatiron), based in New York, NY. Dedicated to learning from the experience of every cancer patient, Flatiron is improving patient care and accelerating cancer research through its products and services. Flatiron’s health technology platform and its creation and analysis of de-identified datasets help oncologists, academics, hospitals, life science researchers, regulators and others work to improve the lives of cancer patients, through both delivery of care and the use of real-world data and evidence to accelerate oncology research and decision-making.
Prior to joining Flatiron, Dr. Vasconcelles was Chief Medical Officer at Unum Therapeutics Inc. (Unum), a Cambridge, MA. cell and gene therapy company developing autologous engineered T cell products for the treatment of cancer. He remains an advisor to Unum. Prior to joining Unum, he spent several years at Takeda/Millennium as Senior Vice President and Head of the Oncology Therapy Area Unit, where he was responsible for the oncology research and development portfolio globally and a member of the R&D Executive Team.
Prior to 2012, Dr. Vasconcelles was Group Vice President and the Global Therapeutic Area Head, Transplant and Oncology, at Genzyme Corporation. At Genzyme he was responsible for clinical development of the transplant and oncology portfolio and a member of the Transplant and Oncology Business Unit Management Team. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Vasconcelles joined Sanofi Oncology as the Head of Personalized Medicine and Companion Diagnostics.
He serves on national and regional boards, including the Board of the Personalized Medicine Coalition, based in Washington, D.C., and the Eastern New England Board of the American Cancer Society, in Boston, MA. Dr. Vasconcelles is also a Special Advisor to Frazier Healthcare Partners’ Life Sciences team, a life sciences venture capital firm based in Menlo Park, CA, and is on the Board of Directors of Molecular Partners, AG.
Dr. Vasconcelles has been a faculty member of the Harvard Medical School since 1996, and is an associate physician at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. He received both his B.A. and M.D. from Northwestern University.
Strategic Partnerships and Alliances Leader, Janssen Pharmaceutical Companies of Johnson and Johnson
Werner Verbiest is Strategic Partnership and Alliances Leader at Janssen Pharmaceutical companies of Johnson and Johnson.
He acts as the interface between the internal Janssen campus research & development community and the external ecosystem. He plays an important role in the development and roll-out of the alliances strategy at the EMEA level, specifically focusing on personalized medicine, diagnostics and health care solutions. Werner represents the Janssen campus toward external (scientific) partners and acts as a trusted counterpart, by demonstrating in depth knowledge of the company's ecosystem, the drug life cycle and scientific insights related to its therapeutic areas, World Without Disease Accelerator, Discovery and Development Platforms. He manages the interactions with both internal (research & development) and external scientific stakeholders, establishing and/or building upon strategic partnerships/alliances with large university or strategic reference hospitals, research institutes, and companies with the aim to create a fertile ground and willingness to work with these external stakeholders on areas that Janssen views as areas for long-term cooperation like research & development, talent exchange, incubator areas, data capturing and analytics, and the World Without Disease ambitions.
In his previous position, Werner Verbiest was the Global Head of Janssen Diagnostics between 2011 and 2019, formed from the legacy organizations he was leading, Virco (infectious diseases pharmacogenomics), Veridex (oncology diagnostics) and the Johnson and Johnson Companion Diagnostics Centre of Excellence. Janssen Diagnostics and its team brought personalized medicine within Johnson & Johnson by incorporating diagnostics, digital diagnostics, and real-world data/health IT solutions together with therapeutics to improve patient outcomes.
Werner started his career at Johnson & Johnson in 1992 focused on HIV drug development and hepatitis B therapeutic vaccine development in the International Clinical Research & Development group of the Janssen Research Foundation. Werner left Janssen in 1998 and became one of the first employees of Virco, a start-up biotechnology company. He played an instrumental and steering role at Virco, which was a company that identified and classified the different strains of the HIV virus. Werner held an instrumental role in its growth in numerous roles of growing responsibility. Those roles included Project and Business Development Director (1998), Managing Director (Virco Ireland, Ltd – Dublin, 1999), Vice President, New Products Marketing and Pharma Business (2000), and General Manager (2001).
Werner rejoined Johnson & Johnson in 2002 through the acquisition of Tibotec-Virco. Werner has built an extensive network of innovators and leaders in the field of diagnostics, digital diagnostics, health care IT solutions, and precision medicine, ranging from academic and biotechnology stakeholders to large companies to policymakers active in health care. He has experience working in a large corporate environment but has also been at the bench in start-up biotechnology and new ventures.
Werner’s voice and expertise has made him a respected voice and advocate for actualizing a precision medicine approach within Johnson and Johnson, but also outside Johnson & Johnson, including several board seats in different “precision medicine solutions” and industry platforms, e.g., EPEMED (Co-founder and Board member of European Personalized Medicine Association); AdvaMedDx (Board Member, Global Diagnostics, Health Care Industry Trade Association); and the Personalized Medicine Coalition (Board Member).